US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pacer WealthShield ETF

30.72

-0.0020-0.01%

Post-market: 30.720.00000.00%16:05 EDT

Volume:3.34K

Turnover:102.70K

Market Cap:26.11M

PE:- -

High:30.74

Open:30.74

Low:30.72

Close:30.73

Loading ...

Overview Company News Filings

Soleno Therapeutics Announces VYKAT(TM) XR Launch

Press Release: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

Closing Bell: ASX flexes 1.38pc gain as Big 4 banks and jobs data deliver

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

This ASX small cap stock is surging 9% on big Fortescue news

Sparc on track to build artificial photosynthesis plant to make hydrogen

The Market Herald

Press Release: Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

ACAD Signs License Deal With Saniona for Rights to Neurology Drug

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Here are 4 biotech stocks that could get a boost from Trump's new regulatory climate

Here are 4 biotech stocks that could get a boost from Trump's new regulatory climate

Biotech-stock investing has one tough test for success - and it's about to get easier

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

Soleno Therapeutics to Participate in Upcoming November Investor Conferences

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PWS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PWS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","market":"US","secType":"STK","nameCN":"Pacer WealthShield ETF","latestPrice":30.723,"timestamp":1744920000000,"preClose":30.725,"halted":0,"volume":3342,"hourTrading":{"tag":"盘后","latestPrice":30.723,"preClose":30.723,"latestTime":"16:05 EDT","volume":2,"amount":61.446,"timestamp":1744920310541},"delay":0,"floatShares":850000,"shares":850000,"eps":0,"marketStatus":"Closed Good Friday","change":-0.002,"latestTime":"04-17 16:00:00 EDT","open":30.74,"high":30.74,"low":30.72,"amount":102701.9939,"amplitude":0.000651,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"BATS","adjPreClose":30.725,"sharesOutstanding":850000,"nav":30.75,"aum":26137500,"bidAskSpread":0.00086,"postHourTrading":{"tag":"盘后","latestPrice":30.723,"preClose":30.723,"latestTime":"16:05 EDT","volume":2,"amount":61.446,"timestamp":1744920310541},"volumeRatio":0.12498410603825683},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","floatShares":850000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.12498410603825683,"shares":850000,"dividePrice":0.43469,"high":30.74,"amplitude":0.000651,"preClose":30.725,"low":30.72,"week52Low":27.39,"pbRate":"--","week52High":32.64,"institutionHeld":0,"latestPrice":30.723,"eps":0,"divideRate":0.014149,"volume":3342,"delay":0,"ttmEps":0,"open":30.74,"prevYearClose":30.4061,"prevWeekClose":30.72,"prevMonthClose":30.818,"prevQuarterClose":30.818,"fiveDayClose":30.71,"twentyDayClose":30.9463,"sixtyDayClose":31.81},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PWS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527538461","title":"Soleno Therapeutics Announces VYKAT(TM) XR Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2527538461","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527538461?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:00","pubTimestamp":1744628400,"startTime":"0","endTime":"0","summary":"First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April  14, 2025  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/14/3060770/0/en/Soleno-Therapeutics-Announces-VYKAT-TM-XR-Launch.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","BK4139","BK4555","BK4585","BK4604","TM","03160","BK4099","BK4588","SLNO"],"gpt_icon":0},{"id":"2524097441","title":"Press Release: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2524097441","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524097441?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:10","pubTimestamp":1743451800,"startTime":"0","endTime":"0","summary":"-- Lead candidate ARD-101 demonstrated clinical activity and was generally. well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome ,with meaningful reductions in hyperphagia (up to a 16-point HQ-CT. reduction, with an average reduction of approximately 8 points among. subjects that followed trial protocol) observed during the 28-day dosing. -- DEXA scans analysis from the PWS Phase 2 trial data measuring body. composition indicated a trend toward decreased body fat (approximately. -- Aardvark bolstered its cash runway through the successful completion of. SAN DIEGO, March 31, 2025  -- Aardvark Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December 31, 2024, and provided business highlights.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","PWS","IPO"],"gpt_icon":0},{"id":"2522653140","title":"Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522653140","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522653140?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer, to be presented at AUA 2025 in April. Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome. Cash balance of $44.8 million as of December 31 2024. Management hosting conference call and webcast today at 4:30 PM ET. “An important dimension of our strategic options exploration has been the development of a portfolio of programs with near-term value drivers that can address under-served markets. While we maintain deep expertise in diseases of the central nervous system, as we evaluate strategic opportunities, the broad drug development expertise of our Team provides flexibility to be opportunistic,” commented Maged Shenouda, CFO of Relmada. “With a $44.8 million cash balance, as of December 31, 2024, and clean balance sheet, we begin the year with solid financial strength.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-reports-fourth-quarter-200500181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALLO","IE00B1B80R65.USD","TS","BK4532","BK4179","BK4563","PWS","LENZ","RLMD","BK4505","CDC","PAM","BK4007","BK4081","BK4139"],"gpt_icon":0},{"id":"2522003463","title":"SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522003463","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522003463?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:46","pubTimestamp":1743079560,"startTime":"0","endTime":"0","summary":"Shares of Soleno TherapeuticsSLNO have rallied 37% in the premarket hours today following the FDA approval of Vykat XR extended-release tablets for treating hyperphagia in adults and children aged four years and older with Prader-Willi syndrome . The company expects to launch the drug in the United States in April 2025.Soleno’s Vykat XR, previously referred to as DCCR, is an innovative, once-daily, proprietary extended-release dosage form that contains diazoxide choline, the crystalline salt form of diazoxide. Although not approved for treating PWS, the parent molecule, diazoxide, treats a few rare diseases in neonates, infants, children and adults.Per the PWS Association USA, approximately one in every 15,000 newborns suffers from this rare genetic disorder. The most common symptom of PWS is hyperphagia, an abnormally increased appetite for food, often leading to excessive eating, which takes a serious toll on the quality of life of patients suffering from it. In the long term, hyperp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/slno-stock-rallies-fda-approval-124600150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","BK4007","LU2065169927.USD","ACAD","CORT","PWS","LU2065171311.SGD","BAYRY","LU2065171402.SGD","LU2065170008.USD","LU1559883803.SGD","SLNO","BK4139","BK4532"],"gpt_icon":0},{"id":"2522935620","title":"Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2522935620","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522935620?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:15","pubTimestamp":1743023700,"startTime":"0","endTime":"0","summary":"First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome. Management to host conference call and webcast today, March 26th, at 5:30pm ET. REDWOOD CITY, Calif., March 26, 2025  -- Soleno Therapeutics, Inc. , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration  has approved VYKAT XR  extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome . Soleno expects VYKAT XR to be available in the U.S. beginning in April 2025.The FDA approval of VYKAT XR was based on an adequate and well-controlled study and safety data from the comprehensive clinical development program. Efficacy was established during the 16-week r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/soleno-therapeutics-announces-u-fda-211500828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PWS","SLNO"],"gpt_icon":0},{"id":"2514839106","title":"Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514839106","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514839106?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"-- Fourth quarter 2024 net revenue from global sales of IMCIVREE  of $41.8 million --. -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 --. -- Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity --. -- FDA approved expanded label for IMCIVREE to include children as young as 2 years old --. -- Raised approximately $75 million in gross proceeds under ATM equity offering program; Cash runway extended into 2027 --. BOSTON, Feb. 26, 2025  -- Rhythm Pharmaceuticals, Inc. , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2024.Today, Rhythm announced a strategic partnership agreement with Trispera Pharma Solutions in Turkey;","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rhythm-pharmaceuticals-reports-fourth-quarter-120000027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4139","PWS","BK4585","RYTM","BK4201","EC"],"gpt_icon":0},{"id":"2507630836","title":"Soleno Therapeutics to Participate in Upcoming February Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2507630836","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507630836?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:05","pubTimestamp":1738184700,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Jan.  29, 2025  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017568/0/en/Soleno-Therapeutics-to-Participate-in-Upcoming-February-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","SLNO","BK4139"],"gpt_icon":0},{"id":"2504941815","title":"Closing Bell: ASX flexes 1.38pc gain as Big 4 banks and jobs data deliver","url":"https://stock-news.laohu8.com/highlight/detail?id=2504941815","media":"Stockheads","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504941815?lang=en_us&edition=fundamental","pubTime":"2025-01-16 14:08","pubTimestamp":1737007691,"startTime":"0","endTime":"0","summary":"Oil prices soar amid supply risks and cold weather","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/ASX-flexes-its-muscles-today.-Picture-via-Getty-Images-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/ASX-flexes-its-muscles-today.-Picture-via-Getty-Images-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/news/closing-bell-asx-flexes-1-3pc-gain-as-big-4-banks-and-jobs-data-deliver/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4110","RC","PWS"],"gpt_icon":0},{"id":"2502576948","title":"Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2502576948","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502576948?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:15","pubTimestamp":1736511300,"startTime":"0","endTime":"0","summary":"-- Preliminary unaudited net revenues from global sales of IMCIVREE (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/10/3007577/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2024-Net-Product-Revenues-Pipeline-Advancements-and-Upcoming-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","PWS","EC"],"gpt_icon":0},{"id":"2501219969","title":"This ASX small cap stock is surging 9% on big Fortescue news","url":"https://stock-news.laohu8.com/highlight/detail?id=2501219969","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501219969?lang=en_us&edition=fundamental","pubTime":"2025-01-07 09:53","pubTimestamp":1736214789,"startTime":"0","endTime":"0","summary":"Sparc Technologies Ltd  shares are having a strong session on Tuesday. At the time of writing, the ASX small cap stock is up 9% to 19 cents. Why is this ASX small cap stock jumping?Investors have been buying the environmental technology company's shares after it released some big news relating to mining giant Fortescue Ltd . According to the release, Sparc Technologies, Fortescue, and the University of Adelaide  will proceed to Stage 2 of the Sparc Hydrogen joint venture. The ASX small cap stock notes that the decision to proceed to Stage 2 reflects several key milestones achieved over recent months. Management believes it is a strong endorsement of the potential of Sparc Hydrogen's novel technology to unlock low-cost green hydrogen via photocatalytic water splitting . What's next?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/07/this-asx-small-cap-stock-is-surging-9-on-big-fortescue-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7129","FMG.AU","BK7507","PWS","BK7036","SPN.AU"],"gpt_icon":0},{"id":"2501292048","title":"Sparc on track to build artificial photosynthesis plant to make hydrogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2501292048","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501292048?lang=en_us&edition=fundamental","pubTime":"2025-01-07 08:03","pubTimestamp":1736208180,"startTime":"0","endTime":"0","summary":"Sparc Technologies  will soon be tapping minds from Fortescue’s former hydrogen division FFI, and the University of Adelaide, as it pushes ahead to stage two of a hydrogen pilot plant project in South Australia.The project is seeking to produce green hydrogen without using an electrolyser – the machines that harness electricity to produce hydrogen gas from non-saline water .It’s a goal that’s previously caught the attention of CSIRO in 2024.Sparc on Tuesday described the use of a “novel reactor technology [that] employs a photocatalyst material and sunlight to produce green hydrogen directly from water” – something called  ‘photocatalytic water splitting’ .The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/sparc-on-track-to-build-artificial-photosynthesis-plant-to-make-hydrogen-2025-01-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7129","PWS","SPN.AU","BK7507","BK7036","FMG.AU"],"gpt_icon":0},{"id":"2492918662","title":"Press Release: Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2492918662","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492918662?lang=en_us&edition=fundamental","pubTime":"2024-12-18 05:05","pubTimestamp":1734469500,"startTime":"0","endTime":"0","summary":"Up to $200 million financing, includes $50 million upfront. REDWOOD CITY, Calif., Dec. 17, 2024  -- Soleno Therapeutics, Inc.  , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates  for up to $200 million.\"This financing significantly strengthens our financial position, providing additional support for anticipated commercial launch activities,\" said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR  extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome  is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","OXM","BK4202","BK4139","SLNO"],"gpt_icon":0},{"id":"2486871681","title":"ACAD Signs License Deal With Saniona for Rights to Neurology Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2486871681","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486871681?lang=en_us&edition=fundamental","pubTime":"2024-11-27 23:06","pubTimestamp":1732719960,"startTime":"0","endTime":"0","summary":"As its first indication, Acadia plans to study SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body. The company is gearing up to initiate a mid-stage study of the candidate for the essential tremor indication in 2026.This strategic move aligns with ACAD’s longstanding commitment to delivering innovative therapies for patients with central nervous system disorders. Per the company, essential tremor has lacked innovative treatment options for decades, highlighting a significant unmet need. Leveraging Acadia’s extensive expertise in developing and commercializing advanced therapies for neurological disorders, the company aims to address this gap through its work with SAN711.Year to date, shares of Acadia have plunged 48.2% compared with the industry’s 7.8% decline.Revenues generated from the sales of Nuplazid are the majority contributor to Acadia’s top line. In the nine months ended Sept. 30, 2024, Nuplazid s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acad-signs-license-deal-saniona-150600406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFXG0V08.USD","PWS","BK4007","BK4578","LU0058720904.USD","LU0823417653.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","LU1571399168.USD","ADP","LU0109394709.USD","LU1228905037.USD","LU1066051498.USD","LU0456855351.SGD","BK4533","LU1691799644.USD","LU0823417737.USD","SG9999003800.SGD","BK4528","LU0321505439.SGD","ALLO","BK4505","LU0122379950.USD","LU0545562505.USD","LU0889565916.HKD","LU0345774631.USD","LU1228905540.USD","LU0225771236.USD","BK4550","BK4583","LU0306806265.USD","BK4592","IE00BYQQ9H92.USD","BK4566","IE00BBT3K403.USD","LU2065169927.USD","ACAD","LU1221951129.SGD","LU0170899867.USD","LU1066053197.SGD","LU2506952170.USD","BK4130","LU0234570918.USD","GILD","IE000M9KFDE8.USD","LU2065171311.SGD","LU2065171402.SGD","LU0690374615.EUR","LU0225284248.USD","PFE"],"gpt_icon":1},{"id":"2486291248","title":"Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486291248","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486291248?lang=en_us&edition=fundamental","pubTime":"2024-11-27 21:00","pubTimestamp":1732712400,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Nov.  27, 2024  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.(“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/27/2988164/0/en/Soleno-Therapeutics-to-Participate-in-Piper-Sandler-36th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4137","PWS","BK4139","HCSG"],"gpt_icon":0},{"id":"2486084930","title":"Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2486084930","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486084930?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:30","pubTimestamp":1732627800,"startTime":"0","endTime":"0","summary":"PDUFA target action date extended by three months to March 27, 2025REDWOOD CITY, Calif., Nov.  26, 2024  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage bioph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987503/0/en/Soleno-Therapeutics-Announces-FDA-Extension-of-Review-Period-for-DCCR-Diazoxide-Choline-Extended-Release-Tablets-in-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","PWS","BK4139"],"gpt_icon":0},{"id":"2485209994","title":"Here are 4 biotech stocks that could get a boost from Trump's new regulatory climate","url":"https://stock-news.laohu8.com/highlight/detail?id=2485209994","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485209994?lang=en_us&edition=fundamental","pubTime":"2024-11-23 21:44","pubTimestamp":1732369440,"startTime":"0","endTime":"0","summary":"Biotech-stock investing has one tough test for success - and it's about to get easier. The key to successful biotech investing is straightforward: Own stocks of companies that get drugs approved. That hasn't been so easy. But the U.S. Food & Drug Administration  has become more flexible about granting new drug approvals, and drugs for rare diseases in particular - which could boost the shares of the four promising biotech firms discussed below.\"Right now, the FDA is at peak flexibility,\" Baird biotech analyst Brian Skorney said in a recent interview. \"The FDA has demonstrated more flexibility every year, over the past 10 years.\". \"There are plenty of drugs that generate a lot of revenue even though there are questions about whether they really work,\" Skorney said.Instead of using clinical benefit as the benchmark, the FDA approved Oxbryta based on studies that showed it reduced a biomarker for the disorder, Skorney said. \"It was a controversial approval decision because of questions ab","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","LU0306807586.USD","BK4550","IE0002270589.USD","LU1894683264.USD","PTCT","LU0889565916.HKD","LU0109394709.USD","BK4599","PWS","BHVN","BK4568","BK4534","LU0225284248.USD","LU0306806265.USD","SG9999011175.SGD","PFE","BK4585","IE00B19Z3B42.SGD","CMS","LU0058720904.USD","LU0985481810.HKD","LU0321505439.SGD","LU2346227817.USD","IE00B19Z3581.USD","BK4007","LU0321505868.SGD","LU1066053197.SGD","SG9999003800.SGD","BK4592","LU1883839398.USD","SG9999002224.SGD","IE00BLSP4452.SGD","LU0234572021.USD","IE00BLSP4239.USD","LU0456855351.SGD","LU1023059063.AUD","APLT","BK4139","BK4208","SGXZ57979304.SGD","SG9999002232.USD","LU1093756325.SGD","LU1066051498.USD","LU0225771236.USD","LU1894683348.USD","LU2637428348.USD","IE000M9KFDE8.USD","BK4581","SLNO"],"gpt_icon":1},{"id":"2484717309","title":"Here are 4 biotech stocks that could get a boost from Trump's new regulatory climate","url":"https://stock-news.laohu8.com/highlight/detail?id=2484717309","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484717309?lang=en_us&edition=fundamental","pubTime":"2024-11-20 03:04","pubTimestamp":1732043040,"startTime":"0","endTime":"0","summary":"Biotech-stock investing has one tough test for success - and it's about to get easier. The key to successful biotech investing is straightforward: Own stocks of companies that get drugs approved. That hasn't been so easy. But the U.S. Food & Drug Administration  has become more flexible about granting new drug approvals, and drugs for rare diseases in particular - which could boost the shares of the four promising biotech firms discussed below.\"Right now, the FDA is at peak flexibility,\" Baird biotech analyst Brian Skorney said in a recent interview. \"The FDA has demonstrated more flexibility every year, over the past 10 years.\". \"There are plenty of drugs that generate a lot of revenue even though there are questions about whether they really work,\" Skorney said.Instead of using clinical benefit as the benchmark, the FDA approved Oxbryta based on studies that showed it reduced a biomarker for the disorder, Skorney said. \"It was a controversial approval decision because of questions ab","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","SG9999003800.SGD","LU1066053197.SGD","PWS","PFE","LU1023059063.AUD","PTCT","SG9999002232.USD","BK4568","IE00B19Z3B42.SGD","BHVN","BK4581","BK4139","LU0321505868.SGD","BK4585","LU0868494617.USD","LU0109394709.USD","LU0320765992.SGD","LU1883839398.USD","LU2637428348.USD","BK4588","IE00BLSP4239.USD","LU0122379950.USD","SG9999001176.USD","SG9999011175.SGD","CMS","LU1093756325.SGD","LU1093756168.USD","SLNO","BK4534","SGXZ57979304.SGD","LU2346227817.USD","SG9999002224.SGD","LU0306807586.USD","BK4533","LU0289739699.SGD","LU0985481810.HKD","LU0456855351.SGD","IE000M9KFDE8.USD","LU0225771236.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","IE0002270589.USD","LU1894683264.USD","LU0058720904.USD","LU0889565916.HKD","LU0170899867.USD","APLT","LU0321505439.SGD","SG9999001176.SGD"],"gpt_icon":1},{"id":"2484621244","title":"Biotech-stock investing has one tough test for success - and it's about to get easier","url":"https://stock-news.laohu8.com/highlight/detail?id=2484621244","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484621244?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:41","pubTimestamp":1731933660,"startTime":"0","endTime":"0","summary":"Here are 4 biotech stocks that could get a boost from a more open FDA regulatory climate. The key to successful biotech investing is straightforward: Own stocks of companies that get drugs approved. That hasn't been so easy. But the U.S. Food & Drug Administration  has become more flexible about granting new drug approvals, and drugs for rare diseases in particular - which could boost the shares of the four promising biotech firms discussed below.\"Right now, the FDA is at peak flexibility,\" Baird biotech analyst Brian Skorney said in a recent interview. \"The FDA has demonstrated more flexibility every year, over the past 10 years.\". \"There are plenty of drugs that generate a lot of revenue even though there are questions about whether they really work,\" Skorney said.Instead of using clinical benefit as the benchmark, the FDA approved Oxbryta based on studies that showed it reduced a biomarker for the disorder, Skorney said. \"It was a controversial approval decision because of questions","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0456855351.SGD","BK4007","LU0321505868.SGD","LU0225771236.USD","LU1894683264.USD","BK4139","LU0320765992.SGD","LU1066053197.SGD","LU1093756168.USD","LU0306806265.USD","BK4592","LU0306807586.USD","LU0985481810.HKD","LU0122379950.USD","LU0234572021.USD","SG9999011175.SGD","SLNO","LU0868494617.USD","BK4588","LU2346227817.USD","LU1883839398.USD","SG9999013999.USD","IE00BLSP4452.SGD","APLT","LU0170899867.USD","BK4208","LU0225284248.USD","IE00B19Z3B42.SGD","LU0109394709.USD","CMS","BHVN","BK4581","PTCT","SG9999001176.SGD","PWS","LU0321505439.SGD","SG9999002224.SGD","BK4568","IE0002270589.USD","LU1066051498.USD","LU1894683348.USD","SGXZ57979304.SGD","SG9999001176.USD","BK4550","PFE","IE00BLSP4239.USD","IE000M9KFDE8.USD","LU1023059063.AUD","LU1093756325.SGD"],"gpt_icon":1},{"id":"2483133089","title":"Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483133089","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483133089?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981587/0/en/Soleno-Therapeutics-Announces-Oral-Presentations-featuring-Diazoxide-Choline-Extended-Release-DCCR-Tablets-in-Prader-Willi-Syndrome-at-ESPE-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","SLNO","BK4139"],"gpt_icon":1},{"id":"2478104926","title":"Soleno Therapeutics to Participate in Upcoming November Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2478104926","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478104926?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:00","pubTimestamp":1730116800,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Oct.  28, 2024   -- Soleno Therapeutics, Inc.  , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 10:00 AM ET Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 4:45 PM ET Event: Jefferies London Healthcare ConferenceDate: Wednesday, November 20, 2024Time: 8:00 AM GT A live audio webcast and replay of the Guggenheim and Jefferies events will be available in the Investors section on the Company’s website at www.soleno.life. AboutSoleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the FDA, supported by its Phase 3 development program, for its lead candidate, DCCR  exten","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/28/2970016/0/en/Soleno-Therapeutics-to-Participate-in-Upcoming-November-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","PWS","BK4139"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PWS\",params:#limit:5,,,undefined,":[{"date":"2025-03-06","symbol":"PWS","amount":0.059681,"announcedDate":"2025-03-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-06","defaultRemindTime":1741271400000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-12","payableDate":"2025-03-06","currency":"USD","dateTimestamp":1741237200000,"payDate":"2025-03-12"},{"date":"2024-12-27","symbol":"PWS","amount":0.206094,"announcedDate":"2024-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-27","defaultRemindTime":1735309800000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-02","payableDate":"2024-12-27","currency":"USD","dateTimestamp":1735275600000,"payDate":"2025-01-02"},{"date":"2024-09-26","symbol":"PWS","amount":0.121716,"announcedDate":"2024-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-26","defaultRemindTime":1727357400000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-02","payableDate":"2024-09-26","currency":"USD","dateTimestamp":1727323200000,"payDate":"2024-10-02"},{"date":"2024-06-27","symbol":"PWS","amount":0.047202,"announcedDate":"2024-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-27","defaultRemindTime":1719495000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-03","payableDate":"2024-06-27","currency":"USD","dateTimestamp":1719460800000,"payDate":"2024-07-03"},{"date":"2024-03-21","symbol":"PWS","amount":0.030854,"announcedDate":"2024-03-20","type":"dividend","market":"US","newRecordDate":"2024-03-22","name":"Pacer WealthShield ETF","recordDate":"2024-03-27","payableDate":"2024-03-22","currency":"USD","dateTimestamp":1710993600000,"payDate":"2024-03-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PWS\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-27","recordDate":"2018-03-28","paymentDate":"2018-03-29","value":0.0522982,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-06-28","value":0.0481106,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-09-27","value":0.1105742,"currency":"USD"},{"executeDate":"2018-12-24","recordDate":"2018-12-26","paymentDate":"2018-12-27","value":0.0682115,"currency":"USD"},{"executeDate":"2019-03-26","recordDate":"2019-03-27","paymentDate":"2019-03-28","value":0.1385698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PWS\",market:\"US\",delay:false,,,undefined,":{}}}